Table 1 Baseline and perioperative characteristics of the two groups
Variables | Crude | p-value | PS Matching | p-value | ||
|---|---|---|---|---|---|---|
Group I (n = 45) | Group C (N = 221) | Group I (n = 45) | Group C (n = 45) | |||
Age (y) | 67.71 ± 7.94 | 71.96 ± 6.19 | < 0.001 | 67.71 ± 7.94 | 69.82 ± 5.38 | 0.143 |
Sex (F/M) | 40 (88.9%)/5 (11.1%) | 203 (91.9%)/18 (8.1%) | 0.519 | 40 (88.9%)/5 (11.1%) | 40 (88.9%)/5 (11.1%) | 1.000 |
Body weight (kg) | 57.10 ± 4.97 | 59.96 ± 7.35 | 0.013 | 57.10 ± 4.97 | 56.84 ± 6.71 | 0.838 |
Hypertension | 30 (66.7%) | 152 (68.8%) | 0.781 | 30 (66.7%) | 31 (68.9%) | 0.822 |
Diabetes | 13 (28.9%) | 65 (29.4%) | 0.944 | 13 (28.9%) | 13 (28.9%) | 1.000 |
Chronic kidney disease | 7 (15.6%) | 50 (22.6%) | 0.292 | 7 (15.6%) | 8 (17.8%) | 0.777 |
Cerebrovascular disease | 6 (13.3%) | 29 (13.1%) | 0.970 | 6 (13.3%) | 6 (13.3%) | 1.000 |
Cardiovascular disease | 9 (20.0%) | 56 (25.3%) | 0.447 | 9 (20.0%) | 10 (22.2%) | 0.796 |
Thyroid disease | 5 (11.1%) | 21 (9.5%) | 0.740 | 5 (11.1%) | 5 (11.1%) | 1.000 |
Antiplatelets | 12 (26.7%) | 834 (37.6%) | 0.165 | 12 (26.7%) | 15 (33.3%) | 0.490 |
Anticoagulants | 1 (2.2%) | 7 (3.2%) | 0.735 | 1 (2.2%) | 1 (2.2%) | 1.000 |
Baseline hemoglobin (g/dL) | 11.41 ± 1.12 | 11.46 ± 1.01 | 0.750 | 11.41 ± 1.12 | 11.40 ± 0.93 | 0.951 |
Preoperative platelet counts (× 109/L) | 267.56 ± 72.33 | 249.21 ± 60.88 | 0.076 | 267.56 ± 72.33 | 253.29 ± 59.81 | 0.311 |
Estimateld blood loss (mL) | 519.90 ± 145.55 | 514.25 ± 199.52 | 0.825 | 519.90 ± 145.55 | 531.54 ± 183.87 | 0.740 |
Postoperative drainage (mL) | 317.40 ± 157.59 | 285.86 ± 135.82 | 0.169 | 317.40 ± 157.59 | 288.86 ± 137.05 | 0.352 |